These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33550095)

  • 1. H7N9 pandemic preparedness: A large-scale production of a split inactivated vaccine.
    Adami EA; Chavez Rico SL; Akamatsu MA; Miyaki C; Raw I; de Oliveira D; Comone P; Oliveira RDN; Sarno de Oliveira ML; Estima Abreu PA; Takano CY; Meros M; Soares-Schanoski A; Lee Ho P
    Biochem Biophys Res Commun; 2021 Mar; 545():145-149. PubMed ID: 33550095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparedness against pandemic influenza: Production of an oil-in-water emulsion adjuvant in Brazil.
    Akamatsu MA; Sakihara VA; Carvalho BP; de Paiva Abrantes A; Takano MAS; Adami EA; Yonehara FS; Dos Santos Carneiro P; Rico S; Schanoski A; Meros M; Simpson A; Phan T; Fox CB; Ho PL
    PLoS One; 2020; 15(6):e0233632. PubMed ID: 32492039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses.
    Wu CY; Chang CY; Ma HH; Wang CW; Chen YT; Hsiao PW; Chang CC; Chan CH; Liu CC; Chen JR
    Vaccine; 2014 Jul; 32(35):4485-4494. PubMed ID: 24962757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Divergent H7 immunogens offer protection from H7N9 virus challenge.
    Krammer F; Albrecht RA; Tan GS; Margine I; Hai R; Schmolke M; Runstadler J; Andrews SF; Wilson PC; Cox RJ; Treanor JJ; García-Sastre A; Palese P
    J Virol; 2014 Apr; 88(8):3976-85. PubMed ID: 24453375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel approach for preparation of the antisera reagent for potency determination of inactivated H7N9 influenza vaccines.
    Schmeisser F; Jing X; Joshi M; Vasudevan A; Soto J; Li X; Choudhary A; Baichoo N; Resnick J; Ye Z; McCormick W; Weir JP
    Influenza Other Respir Viruses; 2016 Mar; 10(2):134-40. PubMed ID: 26616263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stockpiled Avian Influenza A(H7N9) Vaccines Induce Robust, Nonneutralizing Functional Antibodies Against Antigenically Drifted Fifth-Wave A(H7N9) Viruses.
    Zhong W; Levine MZ
    J Infect Dis; 2019 Sep; 220(8):1276-1280. PubMed ID: 31169293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H7N9: can H7N3 live-attenuated influenza vaccine be used at the early stage of the pandemic?
    Rudenko L; Isakova-Sivak I; Rekstin A
    Expert Rev Vaccines; 2014 Jan; 13(1):1-4. PubMed ID: 24308582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination.
    El Sahly HM; Atmar RL; Patel SM; Bellamy A; Liu L; Hong W; Zhu H; Guan Y; Keitel WA;
    Vaccine; 2019 May; 37(19):2561-2568. PubMed ID: 30955980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic and mucosal humoral immune responses induced by the JY-adjuvanted nasal spray H7N9 vaccine in mice.
    Xu J; Li S; Wang X; Liu J; Shan P; Zhou Y; Zhao J; Wang Z; Xu C; Chen M; Chen Z; Zhao K; Qu D
    Emerg Microbes Infect; 2018 Aug; 7(1):140. PubMed ID: 30076293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets.
    Pillet S; Racine T; Nfon C; Di Lenardo TZ; Babiuk S; Ward BJ; Kobinger GP; Landry N
    Vaccine; 2015 Nov; 33(46):6282-9. PubMed ID: 26432915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tackling a novel lethal virus: a focus on H7N9 vaccine development.
    Isakova-Sivak I; Rudenko L
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28532182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: A phase I/II, prospective, randomized, open-label trial.
    Wu UI; Hsieh SM; Lee WS; Wang NC; Kung HC; Ou TY; Chen FL; Lin TY; Chen YC; Chang SC
    Vaccine; 2017 Jul; 35(33):4099-4104. PubMed ID: 28668573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Whole, Inactivated, Low Pathogenicity Influenza A(H7N9) Vaccine against Antigenically Distinct, Highly Pathogenic H7N9 Virus.
    Hatta M; Zhong G; Chiba S; Lopes TJS; Neumann G; Kawaoka Y
    Emerg Infect Dis; 2018 Oct; 24(10):1910-1913. PubMed ID: 30226171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-lasting protective immunity against H7N9 infection is induced by intramuscular or CpG-adjuvanted intranasal immunization with the split H7N9 vaccine.
    Zhou Y; Li S; Bi S; Li N; Bi Y; Liu W; Wang B
    Int Immunopharmacol; 2020 Jan; 78():106013. PubMed ID: 31806571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivated Antigen of the H7N9 Influenza Virus Protects Mice from Its Lethal Infection.
    Seo SH; Kim HS
    Viral Immunol; 2016 May; 29(4):235-43. PubMed ID: 26910526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice.
    Wang Y; Wu J; Xue C; Wu Z; Lin Y; Wei Y; Wei X; Qin J; Zhang Y; Wen Z; Chen L; Liu GD; Cao Y
    Antiviral Res; 2017 Jul; 143():97-105. PubMed ID: 28408133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of influenza A(H7N9) candidate vaccine viruses with improved hemagglutinin antigen yield in eggs.
    Ridenour C; Johnson A; Winne E; Hossain J; Mateu-Petit G; Balish A; Santana W; Kim T; Davis C; Cox NJ; Barr JR; Donis RO; Villanueva J; Williams TL; Chen LM
    Influenza Other Respir Viruses; 2015 Sep; 9(5):263-70. PubMed ID: 25962412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunocapture isotope dilution mass spectrometry in response to a pandemic influenza threat.
    Pierce CL; Williams TL; Santana WI; Levine M; Chen LM; Cooper HC; Solano MI; Woolfitt AR; Marasco WA; Fang H; Donis RO; Barr JR
    Vaccine; 2017 Sep; 35(37):5011-5018. PubMed ID: 28774565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Considerations for the rapid deployment of vaccines against H7N9 influenza.
    Chua BY; Brown LE; Jackson DC
    Expert Rev Vaccines; 2014 Nov; 13(11):1327-37. PubMed ID: 25017993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.
    Leung HC; Chan CC; Poon VK; Zhao HJ; Cheung CY; Ng F; Huang JD; Zheng BJ
    Emerg Microbes Infect; 2015 Apr; 4(4):e22. PubMed ID: 26038770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.